Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 2, 2011, Pages 263-269

  Catala L ^a,b,c   Orcau, A ^a,b,d   De Olalla, P García ^a,b,d   Millet, J P ^a,b,d,e   Rodriguez Mondragon A ^a,b,c   Cayla J A ^a,b,d,e  

^a TB HIV Working Group   (United States)

^b AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

AIDS; Causes of death; Cohort study; Cox regression; Risk factor; Survival analysis; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CAUSE OF DEATH; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL CLASSIFICATION OF DISEASES; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SHORT COURSE THERAPY; SPAIN; SURVIVAL; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 78651453818     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. World Health Organization. Tuberculosis and HIV. Geneva, Switzerland: WHO, 2010. http://www.who.int/hiv/topics/tb/en/index.html. Accessed June 2010.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129. (Pubitemid 34786200)
3. Muga R, Ferreros I, Langohr K, et al., Spanish Multicenter Study Group of Seroconverters (GEMES). Changes in the incidence of tuberculosis in a cohort of VIH-seroconverters before and after the introduction of TARGA. AIDS 2007; 21: 2521-2527.
4. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 326-331. (Pubitemid 32435996)
5. Girardi E, Antonnucci G, Vancore P. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
6. Girardi E, Antonucci G, Vanacore P, et al., GISTA-SIMIT Study Group. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24: 11-17.
7. Santoro-Lopez G, de Pinho A M, Harrison L H, Schechter M. Reduce risk of tuberculosis among Brazilian patients with advanced human immunoDeficiency virus infection treated with highly active antiviral therapy. Clin Infect Dis 2002; 34: 543-546.
8. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239-250.
9. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172: 123-127.
10. Dheda K, Lampe F C, Johnson M A, Lipman M C. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-1676.
11. World Health Organization. Global tuberculosis control: surveillance, planning, fi nancing. WHO report 2007. WHO/HTM/TB/2007.362. Geneva, Switzerland: WHO, 2007. http://www.who.int/tb/publications/global-report/2006/en/ Accessed June2010.
12. Whalen C C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14: 1219-1228.
13. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva, Switzerland: WHO, 2009. http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf Accessed June 2010.
14. Abdool Karim S S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
15. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy. Ann Intern Med 2008; 149: 289-299.
16. Rubio R, Berenguer J, Miró J M, et al. Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunoDeficiency virus infection in 2002. Enferm Infecc Microbiol Clin 2002; 20: 244-303. [Spanish]
17. Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105-110.
18. Davies P D. The role of DOTS in tuberculosis treatment and control. Am J Respir Med 2003; 2: 203-209.
19. Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B. Prevention of tuberculosis in people living with HIV. Clin Infect Dis 2010; 50 (Suppl 3): S215-S222.
20. World Medical Association. Declaration of Helsinki-Ethical principles for medical research involving human subjects. Ferney-Voltaire, France: WMA. http://www.wma.net/en/30publications/10policies/b3/index.html Accessed December 2010.
21. Boletín Ofi cial del Estado. Ley Orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter Personal. Madrid, Spain. http://www.boe.es/aeboe/consultas/bases-datos/doc.php?id=BOE-A-1999-23750 Accessed December 2010.
22. Gracia de la Hera M, Ferreros I, del Amo J, et al., GEMES Collaboration. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 2004; 58: 944-950.
23. Miller L C, Kerr T, Strathdee A S, Li K, Wood E. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J 2007; 4: 1-7.
24. Cascade Collaboration. Time from HIV seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355: 1131-1137.
25. Porter K, Babiker A, Bhaskaran K, et al., CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362: 1267-1274.
26. Moreno S, Jarrin I, Iribarren J A, et al., CoRIS-MD. Inci - dence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis 2008; 12: 1393-1400.
27. Borrell C, Rodriguez-Sanz M, Pasarín M, et al. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socio-economic group in a country with a National Health System? Eur J Public Health 2006; 16: 601-608.
28. Caylà J A, Rodrigo T, Ruiz-Manzano J, et al., Working Group on Completion of Tuberculosis Treatment in Spain (Study ECUTTE). Tuberculosis treatment adherence and fatality in Spain. Respir Res 2009; 10: 121-131.
29. Hernandez-Aguado I, Ramos-Rincon J M, Aviñio M J, Gonzalez-Aracil J, Pérez-Hoyos S, de la Hera M G, Valencian Epidemiology and Prevention of HIV Disease Study Group. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol 2001; 17: 539-544.
30. Díez M, Bleda M J, Alcaide J, et al., Multicentre Project for Tuberculosis Research Study Group. Determinants of patient delay among tuberculosis cases in Spain. Eur J Public Health 2004; 14: 151-155.
31. Sobrino-Vegas P, García-San Miguel L, Caro-Murillo A M, et al., CoRIS. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224-230.
32. Instituto Nacional de Estadística [sede web]. Tablas de mortalidad de la población de España 1992-2005. Madrid, Spain: www.ine.es.http://www.ine.es/jaxi/tabla.do?path=/t20/p319a/1992-2005/l0/ &file=01001.px&type=pcaxis Accessed June 2010. [Spanish]
33. Public Health Agency of Barcelona. La salut a Barcelona 2008. Barcelona, Spain: Public Health Agency of Barcelona, 2008. http://www.aspb.es/quefem/docs/ Salut-bcn-2008.pdf Accessed June 2010. [Catalan].
34. Geng E, Kreiswirth B, Burzyski J, Schuluger N. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 2005; 293: 2740-2745.
35. Centers for Diseases Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC and Infectious Disease Society of America. MMWR 2003; 52: 1-80.
36. Lifson A R, INSIGHT Cause of Death Writing Group, Belloso W H, Carey C, Davey R T, et al. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008; 9: 177-185.
37. de la Fuente L, Brugal M T, Domingo-Salvany A, Bravo M J, Neira-León M, Barrio G. [More than thirty years of illicit drugs in Spain: a bitter story with some messages for the future]. Rev Esp Salud Publica 2006; 80: 505-520. [Spanish]
38. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 2010; 13: 1.